Logo - springer
Slogan - springer

Biomedical Sciences | Purinergic Signalling - incl. option to publish open access (Editorial Board)

Purinergic Signalling

Purinergic Signalling

The Official Journal of the International Purine Club

Editor-in-Chief: Geoffrey Burnstock

ISSN: 1573-9538 (print version)
ISSN: 1573-9546 (electronic version)

Journal no. 11302

$99.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 4 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Prof. G. Burnstock, Autonomic Neuroscience Institute, Royal Free and University College Medical School, London, UK

Associate Editors

Molecular Biology of Purinergic Receptors
Jean-Marie Boeynaems, Université Libre de BruxellesBrussels, Belgium - P2Y receptors
Michael Jarvis, AbbVie, North Chicago, IL, USA – P2X receptors (pain)

Medicinal Chemistry & Pharmacology
Ad IJzerman, Leiden University, The Netherlands – P1 receptors
Kenneth A. Jacobson, National Institutes of Health, Bethesda, MD, USA – P1/P2Y receptors

Ectoenzymes, Development & Stem Cells
Nicholas Dale, University of WarwickCoventry, UK
Jean Sévigny, Université Laval, Québec, Canada 
Herbert Zimmermann, J.W. Goethe-University, Frankfurt, Germany  

Central Nervous System & Pain
Maria Abbracchio, University of Milan, Italy – P2Y receptors/glia
Holger Eltzschig, University of Colorado, USA - kidney/heart/lung/gut
Peter Illes, University of Leipzig, Germany – Neurodegeneration/P2X3 receptors
Kazuhide Inoue, Kyushu University, Fukuoka, Japan – P2X4 receptors/pain
Charles Kennedy, University of Strathclyde, UK - Urinogenital system and more
Beáta Sperlágh, Hungarian Academy of Sciences, Budapest, Hungary – P2X7 receptors/pain/behaviour

Peripheral Nervous System & Physiological Roles
Timothy R Arnett, University College London, UK – Musculo-skeletal system
Vera Ralevic, University of Nottingham, UK – Cardiovascular system
Jean-Pierre Timmermans, Universiteit Antwerpen, Belgium – Respiratory and gastrointestinal systems

Pathophysiology & Clinical
Wolfgang Junger, Beth Israel Deaconess Medical Center, Boston, MA, USA
Simon Robson, Harvard Medical SchoolBoston, MA, USA

Immunology, Genetics & P2X7 Receptors
Francesco Di Virgilio, University of Ferrara, Italy

Stem cells, Neuroscience, Cancer & Inflammation
Henning Ulrich, University of Sao Paolo, Brazil

Maria Abbracchio, University of Milan, Italy
Nicholas Dale, University of Warwick, Coventry, UK

Editorial Board
Jolanta Baranska, Polish Academy of Sciences, Warsaw, Poland; Ana Maria Battastini, The Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Luiz Belardinelli, Gilead, Palo Alto, CA, USA; Michael Blackburn, University of Texas, Houston, TX, USA; Stefan Boehm, Medical University of Vienna, Austria; Pier Borea, University of Ferrara, Italy; Richard C. Boucher, The University of North Carolina at Chapel Hill, NC, USA; Bruce Cronstein, NYU School of Medicine, NY, USA; Robson Coutinha-Silva, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Rodrigo Cunha, University of Coimbra, Portugal; Jeff Dixon, The University of Western Ontario, London, ON, Canada; Jonathan A. DranoffUniversity of Arkansas for Medical Sciences, AR, USA; George Dubyak, Case Western Reserve University School of Medicine, Cleveland, OH, USA; William R. Dunn, University of Nottingham, Nottingham, UK; David Erlinge, Lund University Hospital, Lund, Sweden; Michel Fausther, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Bilha Fischer, Bar-Ilan University, Ramat-Gan, Israel; Anthony Ford, Afferent Pharmaceuticals, San Mateo, CA, USA; Samuel J. Fountain, University of East Anglia, UK; Christian Gachet, University of Strasbourg, Strasbourg, France; Alison Gartland, University of Sheffield, UK; George Hasko, Rurtgers New Jersey Medical School, Newark, NJ, USA; Brian Gulbransen, Michigan State University, East Lansing, MI, USA; Gary Housley, University of Auckland, New Zealand; Pablo Huidobro-Toro, Pontifical Catholic University of Chile, Santiago, Chile; Paul Insel, University of California San Diego, CA, USACharles Kennedy, University of Strathclyde, Strathclyde, UK; Baljit Khakh, University of California, Los Angeles, CA, USA; Yong-Chul Kim, Gwangju Institute of Science & Technology, Korea; Schuichi Koizumi, University of Yamanashi, Japan; Oleg Krishtal, Bogomoletz Institute of Physiology, Kiev, Ukraine; Ivar von Kügelgen, University of Bonn, Bonn, Germany; Eduardo Lazarowski, The University of North Carolina at Chapel Hill, NC, USA; Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA; Maria Teresa Miras-Portugal, Complutense University of Madrid, Spain; Christa Müller, University of Bonn, Germany; Pablo Pelegrín, Murcia Biomedical Research Institute, Murcia, Spain; Jesus Pintor, Complutense University of Madrid, Spain; Michael W. Salter, University of Toronto, OT, Canada; Jana Sawynok, Dalhousie University, Halifax, Nova Scotia, Canada; Ana Sebastão, University of Lisbon, Portugal; Philippe Séguela, McGill University, Montreal, Canada; Eugene Silinsky, Northwestern University Medical School, Chicago, IL, USA; Michail Sitkovsky, Northeastern University, Boston, MA, USA; Randy Sprague, Saint Louis University, MO, USA; Makoto Tsuda, Kyushu University, Japan; Alex Verkhratsky, University of Manchester, UK ; Mark Voigt, Saint Louis University, MO, USA; Cinzia Volonte, Fondazione Santa Lucia/CNR, Rome, Italy; Gary Weisman, University of Missouri, Columbia, MO, USA; James S. WileyUniversity of Melbourne, Australia; Gennady Yegutkin, Turku University, Finland; Yong Tang, Chengdu University of Traditional Medicine, China

Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2016 Impact Factor
  • 3.022
  • Aims and Scope

    Aims and Scope


    Nucleotides and nucleosides are primitive biological molecules that were utilized early in evolution both as intracellular energy sources and as extracellular signalling molecules. ATP was first identified as a neurotransmitter and later as a co-transmitter with all the established neurotransmitters in both peripheral and central nervous systems. Four subtypes of P1 (adenosine) receptors, 7 subtypes of P2X ion channel receptors and 8 subtypes of P2Y G protein-coupled receptors have currently been identified. Since P2 receptors were first cloned in the early 1990’s, there is clear evidence for the widespread distribution of both P1 and P2 receptor subtypes in neuronal and non-neuronal cells, including glial, immune, bone, muscle, endothelial, epithelial and endocrine cells.

    There is both short-term purinergic signalling in transmission and secretion and long-term (trophic) signalling in controlling cell proliferation, differentiation, motility and death in development and regeneration and there is increasing interest in the roles of purines and pyrimidines in pathophysiological conditions and their therapeutic potential in disease. At the molecular level, rapid progress has been made in understanding the mechanisms of nucleotide and nucleoside release, their extracellular metabolism, the intracellular signalling cascades elicited by receptor activation and the cross-talk with other essential signalling pathways.

    The rapidly growing interest in purinergic signalling with its exceptionally wide spectrum of signalling functions in health and disease makes this journal devoted to purinergic signalling attractive to both basic scientists and clinicians.

    Purinergic Signalling publishes:
    Original Research Articles, Short Communications, Reviews, Commentaries, ’Hot’ Topics and Controversies, as well as Meeting Reports and Book Reviews.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Author Academy: Training for Authors
  • Endnote style (zip, 1 kB)
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer Science+Business Media Dordrecht

Alerts for this journal


Get the table of contents of every new issue published in Purinergic Signalling.